What is the official ID of this bill?

The official print number for this legislation is S 2205.

When did the legislative process begin?

The process officially started on 2023-06-22.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/118/bills/s2205/BILLS-118s2205is.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

Who is the primary sponsor?

The primary sponsor is Sen. Lee, Mike [R-UT].

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Analysis and Potential Impact of S 2205

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Streamlining Pancreatic Islet Cell Transplantation for Diabetes Patients.

Q: What are the main provisions?

Key points include: Pancreatic islet cells (used for diabetes treatment) are now legally treated as organs, not drugs or biological products. This change is intended to speed up and simplify access to these cell transplants for patients by bypassing lengthy drug approval processes. The Secretary of Health and Human Services must update regulations within one year to implement this new classification.

This Act changes how pancreatic islet cells, harvested from deceased donors and used to treat diabetes, are regulated. Instead of being classified as drugs or biological products, they will be regulated as organs for transplantation. This aims to simplify procedures and potentially increase the availability of this life-saving therapy for patients with severe Type 1 diabetes.

Key points

Pancreatic islet cells (used for diabetes treatment) are now legally treated as organs, not drugs or biological products.

This change is intended to speed up and simplify access to these cell transplants for patients by bypassing lengthy drug approval processes.

The Secretary of Health and Human Services must update regulations within one year to implement this new classification.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

ISLET Act

Print number: S 2205

Sponsor: Sen. Lee, Mike [R-UT]

Process start date: 2023-06-22

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash-preview-09-2025

Source data: api.congress.gov

AI work logs for this document launch

Streamlining Pancreatic Islet Cell Transplantation for Diabetes Patients.

Key Questions about Streamlining Pancreatic Islet Cell Transplantation for Diabetes Patients.